SNY’s COO, Hanspeter Spek, just answered a CC question about Lovenox pricing in the US market. This was a perfect set-up to comment on an authorized generic, but Spek uttered nary a peep about an AG in his detailed reply.
The evidence is mounting that zipjet nailed the game-theory analysis and that SNY will not launch an AG as long as there is only one FDA-approved generic in the market (#msg-33857504).
Market Data 
Markets 
AI
